Is there an established KPV dose?

No. KPV is investigational with a preclinical evidence base, so there is no label or validated human dose. Community protocols report roughly 200–500 mcg/day, oral or subcutaneous, provided here for education only and not as instructions for use.

KPV is a tripeptide — lysine-proline-valine — corresponding to the C-terminal fragment of the hormone α-MSH. It is studied for anti-inflammatory effects, particularly in the gut, and is of interest in conditions like inflammatory bowel disease, mostly in preclinical models.

What is KPV's regulatory status?

It was on the FDA 503A Category 2 list, removed in April 2026 after nominations were withdrawn, and is scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026. Removal from Category 2 is not approval.

Dosage Guide · Research-only / preclinical

KPV Dosage: What Community Protocols Report

Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced

← KPV encyclopedia entry · See also: BPC-157 dosage · Regulatory tracker

⚠️ Preclinical — no validated human dose

KPV is investigational and not FDA approved, with an evidence base that is largely preclinical. There is no label or validated human dose. The figures below reflect community practice, documented for education — not instructions for use.

The short version

KPV is a tripeptide — lysine-proline-valine — that corresponds to the C-terminal end of α-melanocyte-stimulating hormone (α-MSH). It carries α-MSH's anti-inflammatory activity without the pigmentation effects of the full hormone, which is why it is studied for inflammatory conditions, especially in the gut (inflammatory bowel disease models). As with most peptides here, the appealing biology lives mostly in animal and cell studies, so any human dose is an extrapolation.

What community protocols report

Parameter	Commonly reported
Amount	~200–500 mcg/day
Route	Oral (for gut focus) or subcutaneous
Pattern	Once daily, time-limited

The route choice tracks the goal: oral dosing is favored when the target is gut inflammation (delivering the peptide where it is meant to act), while subcutaneous is used for a more systemic intent. Both are community conventions rather than validated regimens.

Where KPV stands legally

KPV was on the FDA 503A Category 2 list and, on April 15, 2026, was among the peptides removed from Category 2 after nominations were withdrawn — which is not approval. It is one of the compounds scheduled for PCAC review on July 23, 2026. Until that concludes it remains outside the approved-medicine framework; see the Regulatory Status Tracker.

Reconstitution basics

Injectable KPV is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water; oral forms are also sold. For the injectable route, the Reconstitution Calculator converts vial strength and diluent volume into an exact draw — though it cannot verify the contents of an unregulated vial.

Frequently asked questions

Does oral KPV survive digestion?

Part of KPV's interest is evidence in gut models that it can act locally on intestinal inflammation, which is the rationale for oral use in that setting; systemic oral bioavailability is a separate, less-settled question.

Is it related to BPC-157?

They are both discussed for gut and inflammation but are unrelated molecules with different mechanisms. See the BPC-157 dosage page.

Is it approved now that it's off Category 2?

No. Removal from Category 2 is procedural; KPV awaits its July 2026 PCAC review and is not an approved medicine.

Sources

Dalmasso G, et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134:166–178.
U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC meeting notice for July 23–24, 2026.

Medical disclaimer: Education only, not medical advice. KPV is investigational and not approved for human use. Dosing figures reflect community reports, not a recommendation. Do not self-administer; consult a licensed clinician.